View of the office building of Chinese pharmaceutical company BeiGene in Suzhou Ctiy, east China's Jiangsu Province on November 22nd, 2019. A Chinese pharmaceutical company has won market approval from the United States Food and Drug Administration for a self-developed lymphoma drug, marking the first entry of an innovative cancer drug from a Chinese company into the US and giving a boost to domestic drugmakers' ambitions to create new treatments for patients around the world. The drug, known as Brukinsa, is a product from Beijing-based BeiGene. It received the FDA's approval and is expected t
Image details
Contributor:
Sipa US / Alamy Stock PhotoImage ID:
2EPB1YMFile size:
46.2 MB (1.4 MB Compressed download)Releases:
Model - no | Property - noDo I need a release?Dimensions:
4928 x 3280 px | 41.7 x 27.8 cm | 16.4 x 10.9 inches | 300dpiDate taken:
22 November 2019Photographer:
CostfotoMore information:
This image could have imperfections as it’s either historical or reportage.
View of the office building of Chinese pharmaceutical company BeiGene in Suzhou Ctiy, east China's Jiangsu Province on November 22nd, 2019. A Chinese pharmaceutical company has won market approval from the United States Food and Drug Administration for a self-developed lymphoma drug, marking the first entry of an innovative cancer drug from a Chinese company into the US and giving a boost to domestic drugmakers' ambitions to create new treatments for patients around the world. The drug, known as Brukinsa, is a product from Beijing-based BeiGene. It received the FDA's approval and is expected to become available to US patients by the end of the year, Wu Xiaobin, BeiGene president, said at a news conference. (Photo by Finn / Costfoto/Sipa USA)